A 24-week trial finds high-phenolic olive oil reduces insulin resistance in type 2 diabetes, but without changing lipids or blood pressure. PICO summary and commentary.
Browsing: Diabetes & Glycaemic Control
A crossover trial finds the Omnipod 5 Activity feature reduces insulin and blunts exercise glucose drops in type 1 diabetes, though hypoglycemia rates were unchanged. PICO summary and commentary.
A mechanistic randomized trial found empagliflozin reduced total-body norepinephrine turnover at 1 day and 12 weeks even as hepatic glucose production rose, with the two changes inversely correlated. PICO summary and expert commentary.
A small crossover trial found almond milk offered no postprandial glycaemic benefit over 2% cow milk in adults with type 2 diabetes, with the primary glucose endpoint null. PICO summary and expert commentary.
A small pilot finds curcumin lowers HbA1c in prediabetic older adults, but without changing weight, lipids, or overall gut microbiome diversity. PICO summary and commentary.
A single-centre randomised controlled trial testing multidisciplinary multifactorial care against standard care in 192 adults with type 2 diabetes, with a modest HbA1c reduction and improved eGFR. PICO summary and expert commentary.
A crossover trial finds orange juice with breakfast raises glucose no more than whole orange or a sugary drink of matched sugar in well-controlled type 2 diabetes. PICO summary and commentary.
A controlled study finds adding vildagliptin to premixed insulin reduces glycaemic variability and improves time in range in type 2 diabetes. PICO summary and commentary.
In adults with type 2 diabetes on basal insulin, once-weekly IcoSema was non-inferior to basal-bolus therapy for HbA1c and superior for weight, insulin dose, and hypoglycaemia. PICO summary and expert commentary.
The phase 3a COMBINE 1 trial finds once-weekly IcoSema lowers HbA1c more than insulin icodec alone while cutting hypoglycemia. PICO summary and expert commentary.